Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VPS4B | O75351 | 1/20 | 0.51 |
| ▸ | VCP | P55072 | 1/20 | 0.51 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.47 |
| ▸ | HTR1F | P30939 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 8/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.44 |
| ▸ | HTR2B | P41595 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5792072 | 0.89 | SIGMAR1 (0.45) | VPS4BVCPBAZ2BSIGMAR1DRD2 | |
| SCHEMBL4903902 | 0.80 | HTR1D (0.69) | BAZ2BHTR1BKMT2AHTR2BHTR2A | |
| SCHEMBL833780 | 0.80 | HTR1B (0.65) | VPS4BVCPBAZ2BHTR1FHTR1B | |
| SCHEMBL833781 | 0.80 | HTR1B (0.65) | VPS4BVCPBAZ2BHTR1FHTR1B | |
| SCHEMBL833788 | 0.80 | HTR1B (0.65) | VPS4BVCPBAZ2BHTR1FHTR1B | |
| SCHEMBL13478770 | 0.80 | KMT2A (0.64) | VPS4BVCPBAZ2BHTR1FHTR1B | |
| SCHEMBL7066276 | 0.80 | NR2E1 (0.63) | HTR2A | |
| SCHEMBL25498044 | 0.79 | VPS4B (0.49) | VPS4BVCPBAZ2BHTR1FHTR1B | |
| SCHEMBL4899304 | 0.78 | HTR1B (0.52) | VPS4BVCPBAZ2BHTR1FHTR1B | |
| SCHEMBL4895910 | 0.78 | HTR1B (0.52) | VPS4BVCPBAZ2BHTR1FHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| CN-102791689-A | 3- (heteroaryl-amino) -1,2,3, 4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD | 2012-11-21 | — | — | CN | disclosed |
| US-7495111-B2 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1893617-A1 | TRICYCLIC COMPOUNDS USEFUL AS SEROTONIN INHIBITORS AND 5-HT1A AGONISTS AND ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2006138549-A1 | TRICYCLIC COMPOUNDS USEFUL AS SEROTONIN INHIBITORS AND 5-HT1A AGONISTS AND ANTAGONISTS | WYETH (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-1651637-A1 | 3-AMINO CHROMAN AND 2-AMINO TETRALIN DERIVATIVES | Wyeth (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | WYETH (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2005012291-A1 | 3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES | WYETH (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | TPH2, HTR2C, HTR7 | VPS4B 3544/4885VCP 4410/4885BAZ2B 4795/4885 |
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | HTR1A, HTR7, HTR3A | VPS4B 4279/4885VCP 4539/4885BAZ2B 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.